HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Supplement Market Growth: Is The Industry In Its Own Way?

This article was originally published in The Rose Sheet

Executive Summary

Longtime supplement industry attorney Scott Bass says supplement manufacturers should work with FDA as an ally, including registering products with the agency pre-market, while FDA's second-in-command for supplement industry oversight, Robert Durkin, says the agency is not interested in preventing more safe products from reaching the market.

You may also be interested in...



Bodybuilding.com Hoists Its Regulatory Experience As Lesson For Compliance

Highlighting dietary supplement sector's self-regulation at a recent supplement industry regulatory conference, the sports nutrition product marketer's chief counsel Bill Carter described his experience in federal court in 2012. He suggested some supplement firms, like Bodybuilding.com previously, don't consider themselves likely to incur litigation or criminal charges linked to regulatory problems when they learn about other businesses that have. "Just because you don't hear about a lot of FDA's office of Criminal Investigations doesn't mean they're not active," he said.

Supplement GMP Inspections Slowing As FDA Makes 'Potential' Data Useful

FDA doesn't expect o continue increasing GMP inspections at the rate established from fiscal 2013 through 2017, says Cara Welch, assistant director of the office in the agency's Office of Dietary Supplement Programs."We're not going to keep growing at that rate because we have a lot of regulations we have to inspect and we're always resource strapped," she said at a recent industry conference.

Industry Eyes NDI Notification Common Ground With Gottlieb-Led FDA

CHPA and CRN look forward to working with FDA to develop a path for the identification of pre-DSHEA ingredients, but say the FDA’s revised draft guidance for new dietary ingredient notifications still hampers innovation.

Related Content

Topics

UsernamePublicRestriction

Register

RS121674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel